As a diagnostic biomarker for LAM, adding VEGF-D in the diagnostic algorithm enabled the diagnosis of LAM without lung biopsy in 83.5% patients with LAM. The gene discussed is VEGFD; the disease is lymphangioleiomyomatosis.